Navigation Links
Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
Date:2/12/2008

ic Chemistry from the University of British Columbia in Vancouver, Canada.

About Mersana Therapeutics, Inc.

Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer-camptothecin conjugate which is currently in Phase 1 clinical trials, and several preclinical oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.

Fleximer(R) is a trademark of Mersana Therapeutics, Inc.


'/>"/>
SOURCE Mersana Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
4. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
5. Nile Therapeutics, Inc. Adds to Executive Management Team
6. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
7. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
8. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
9. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
10. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
11. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Small addition to cancer drug may make big difference 2Small addition to cancer drug may make big difference 3H1N1 influenza adopted novel strategy to move from birds to humans 2H1N1 influenza adopted novel strategy to move from birds to humans 3H1N1 influenza adopted novel strategy to move from birds to humans 4Brooding fishes take up nutrients from their own children 2OptoElectronix Offers Lighting Manufacturers A Unique Integrated LED Light Engine With 1 000 Lumens Light Output 50007 1OptoElectronix Offers Lighting Manufacturers A Unique Integrated LED Light Engine With 1 000 Lumens Light Output 50007 2OptoElectronix Offers Lighting Manufacturers A Unique Integrated LED Light Engine With 1 000 Lumens Light Output 50007 3World Nanomedicine Market to Cross 24160 Billion by 2015 According to New Report by Global Industry Analysts Inc 12778 1World Nanomedicine Market to Cross 24160 Billion by 2015 According to New Report by Global Industry Analysts Inc 12778 2World Nanomedicine Market to Cross 24160 Billion by 2015 According to New Report by Global Industry Analysts Inc 12778 3Construction Begins 3A Nemours Children 26apos 3Bs Hospital And Pediatric Health Campus 50005 1Construction Begins 3A Nemours Children 26apos 3Bs Hospital And Pediatric Health Campus 50005 2Construction Begins 3A Nemours Children 26apos 3Bs Hospital And Pediatric Health Campus 50005 3Construction Begins 3A Nemours Children 26apos 3Bs Hospital And Pediatric Health Campus 50005 4